Qiming Corporate GP VI, Ltd. sold $3.3M of ALMR (indirect holdings)
Qiming Corporate GP VI, Ltd. sold 111,313 indirectly-held shares of Alamar Biosciences, Inc. (ALMR) at $29.89 ($3.33M total) across 4 trades on 2026-11-03. Filed jointly with Qiming Managing Directors Fund VI, L.P. (10% owner), Qiming Venture Partners VI, L.P. (10% owner), Qiming GP VIII, LLC (10% owner), Qiming Venture Partners VIII Investments, LLC (10% owner), Qiming GP VIII-HC, LLC (10% owner) and Qiming Venture Partners VIII-HC, L.P. (10% owner).
How this was made
The 30-second read
Why it matters
The insider sale may prompt short‑term price softness, but given the modest size relative to market cap, long‑term impact is limited.
Market read
Primary relevance is to ALMR shareholders; broader market impact is minimal.
What to watch
Potential upcoming financing needs or strategic repositioning by the insider that are not disclosed.
Background
Form 4 filing discloses a direct sale of ALMR shares by a 10% owner, providing the first public notice of this transaction.
Ticker impact
Qiming Corporate GP VI, Ltd. sold 111,313 shares of ALMR for $3.33M, reducing its indirect stake to 1.65M shares.
likely slight downward pressure as the market prices in the insider sell
The sale represents a modest cash‑out by a large shareholder; such transactions often cause short‑term selling pressure, though the size is not material for the company.
Market effects
Minimal impact on the broader biotech sector; insider sales are common and do not alter sector dynamics.
No significant regional effect; the transaction is confined to ALMR shareholders.
Limited global relevance; only relevant to investors tracking ALMR.
Counterpoint
The insider may be reallocating capital without negative outlook; the sale could be neutral for the stock.
Key entities
- companyAlamar Biosciences, Inc.
US biotech company (ticker ALMR) whose insider sold shares.
- investorQiming Corporate GP VI, Ltd.
10% owner executing the sale.



